Stock to buy after Q1 results 2026: Emkay sees over 32% upside in this healthcare stock
Emkay Global Financial Services maintains its 'Buy' rating on Park Medi World, raising the target price to ₹375 following strong June quarter results, with revenue growth of 19% YoY and profit after tax increasing by 31%. Capacity expands amid risks in government collections.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Wow
0
Sad
0
Angry
0
Comments (0)